NFKB1 and myelodysplastic syndrome: Several mechanisms explaining the hematologic improvement achieved by iron chelators in MDS patients have been proposed: a direct effect on the MDS clone or bone marrow microenvironment; an increase in iron release from iron stores; an alteration in NF-κB expression; an inhibition of m-TOR signaling; and reduced oxidative stress [10].